Ehlers-Danlos syndrome musculocontractural type 2

Summary
Definition
An Ehlers-Danlos syndrome that is characterized by progressive multisystem fragility-related manifestations, including joint dislocations and deformities; skin hyperextensibility, bruisability, and fragility, with recurrent large subcutaneous hematomas; cardiac valvular, respiratory, gastrointestinal, and ophthalmologic complications; and myopathy, featuring muscle hypoplasia, muscle weakness, and an abnormal muscle fiber pattern in histology in adulthood, resulting in gross motor developmental delay and that has_material_basis_in homozygous mutation in the DSE gene on chromosome 6q22.
Super Class
Ehlers-Danlos syndrome autosomal recessive disease
Disease Ontology
DOID:0080737
Mondo Disease Ontology
OMIM
Related Genes
Displaying 1 entry
Gene ID Gene Symbol Description Source
29940 DSE dermatan sulfate epimerase
Displaying 1 entry
Gene ID Gene Symbol Description Source
212898 Dse dermatan sulfate epimerase
The Human Phenotype Ontology
Displaying entries 31 - 40 of 85 in total
HPO ID HPO Term
HP:0001182 Tapered finger
HP:0001238 Slender finger
HP:0001324 Muscle weakness
HP:0001363 Craniosynostosis
HP:0001519 Disproportionate tall stature
HP:0001581 Recurrent skin infections
HP:0001582 Redundant skin
HP:0001627 Abnormal heart morphology
HP:0001654 Abnormal heart valve morphology
HP:0001892 Abnormal bleeding
Displaying all 2 entries
Gene ID Gene Symbol Description
113189 CHST14 carbohydrate sulfotransferase 14
29940 DSE dermatan sulfate epimerase

About Release Notes Help Feedback

Click here to visit the beta site.


International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.1.0

Last updated: December 9, 2024